20/20 Biolabs, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
20/20 BioLabs (Nasdaq: AIDX), a $6.1M-asset company, executed a two-year contract with Vermont for OneTest Premium cancer screening covering ~4,500 firefighters with revenue expected in Q4 2026. The company raised $6M in Series E preferred stock in H1 2026, boosting cash to $3.63M (vs. $1.03M at year-end 2025). Nine-month OneTest revenue grew 4.1% to $1.36M with gross margin expanding to 32.8%; Q3 revenue declined YoY to $0.38M due to testing timing. The company introduced a lab franchise model and plans 2027 licensing of its protein tumor marker technology.
Why this rating
Vermont contract + franchise/licensing strategy are meaningful distribution expansions relative to $1.36M 9-month revenue base. $6M Series E funding (66% of total assets) is material for cash runway. However, Q3 revenue decline and $5.06M 9-month net loss temper outlook.
Tradability signal
NO TRADE
No trade: price $0.19 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.19 ▼ 1.32% | at our read · unknown $0.19 | +10 min · unknown $0.19 ▼ 1.58% | +30 min · unknown $0.19 ▼ 1.05% | +1 hr · unknown $0.19 ▼ 2.11% | +4 hrs · unknown $0.18 ▼ 3.68% |
The stock had already moved +1.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.